AI Article Synopsis
- The study used meta-analysis to assess the relationship between transforming growth factor beta 1 (TGF-β1) expression and papillary thyroid carcinoma (PTC), reviewing 6 studies with 617 samples.
- It found that TGF-β1 was positively expressed in 64.63% of PTC patients, with an overall expression rate of 46.19%.
- The analysis showed a significant link between TGF-β1 expression and lymphatic metastasis, suggesting TGF-β1 could be a predictor for PTC prognosis related to lymph node involvement.
Article Abstract
To comprehensively evaluate the association between the positive expression rate of transforming growth factor beta 1 (TGF-β1) and papillary thyroid carcinoma (PTC) by using Meta-analysis.Search the CNKI, Wan fang, VIP and PubMed database for accumulating papers studying on the relationship between the positive expression of TGF-β1 and PTC in Chinese and English. Revman 5.3 was used to analyze the included trials.A total of 6 studies comprising 617 samples was included in the meta-analysis. The TGF-β1 were found in 243 patients (64.63%) of 376 PTC patients, and the total positive expression rate is 46.19%. Performing the subgroup analysis according to age, gender, lymphatic metastasis and TNM, the results showed that there was a significant association between the positive expression rate of TGF-β1 and lymphatic metastasis (=5.44, 95%3.31-8.93, <0.000 01).This meta-analysis confirmed significant associations between the expression of TGF-β1 and PTC with lymph node metastasis. TGF-β1 may be used as a predictive factor for prognosis of PTC with lymph node metastasis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.13201/j.issn.1001-1781.2017.18.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!